Skip to content
10-Q

Quarterly Report

SYNAGEVA BIOPHARMA CORP

0001193125-15-161923

← back to feed
Filed
Apr 30, 2015 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2015 · Apr 24, 2015 37.15M sh
Shares Diluted Q1 2015 · Mar 31, 2015 36.5M sh
Shares Diluted Q1 2015 · Mar 31, 2014 31.34M sh
Capex Q1 2015 · Mar 31, 2015 $1.78M
Capex Q1 2015 · Mar 31, 2014 $3.25M
Short Term Investments Q1 2015 · Mar 31, 2015 $611.98M
Short Term Investments Q1 2015 · Dec 31, 2014 $364.26M
Cash And Equivalents Q1 2015 · Mar 31, 2015 $98.58M
Cash And Equivalents Q1 2015 · Dec 31, 2014 $82.65M
Cash And Equivalents Q1 2015 · Mar 31, 2014 $152.33M
Cash And Equivalents Q1 2015 · Dec 31, 2013 $62.14M
Stockholders Equity Q1 2015 · Mar 31, 2015 $735.13M
Stockholders Equity Q1 2015 · Dec 31, 2014 $473.24M
Current Liabilities Q1 2015 · Mar 31, 2015 $27.85M
Current Liabilities Q1 2015 · Dec 31, 2014 $25.24M
Total Liabilities Q1 2015 · Mar 31, 2015 $33.42M
Total Liabilities Q1 2015 · Dec 31, 2014 $30.96M
Current Assets Q1 2015 · Mar 31, 2015 $722.28M
Current Assets Q1 2015 · Dec 31, 2014 $457.83M
Total Assets Q1 2015 · Mar 31, 2015 $768.55M
Total Assets Q1 2015 · Dec 31, 2014 $504.2M
Eps Diluted Q1 2015 · Mar 31, 2015 −$1.63
Eps Diluted Q1 2015 · Mar 31, 2014 −$1.16
Eps Basic Q1 2015 · Mar 31, 2015 −$1.63
Eps Basic Q1 2015 · Mar 31, 2014 −$1.16
Sga Expense Q1 2015 · Mar 31, 2015 $21.67M
Sga Expense Q1 2015 · Mar 31, 2014 $9.8M
Rd Expense Q1 2015 · Mar 31, 2015 $38.21M
Rd Expense Q1 2015 · Mar 31, 2014 $27.87M
Net Income Q1 2015 · Mar 31, 2015 −$59.6M
Net Income Q1 2015 · Mar 31, 2014 −$36.42M
Operating Income Q1 2015 · Mar 31, 2015 −$59.17M
Operating Income Q1 2015 · Mar 31, 2014 −$36.48M
Revenue Q1 2015 · Mar 31, 2015 $927K
Revenue Q1 2015 · Mar 31, 2014 $1.59M